Cereno Scientific to present CS585’s preclinical data at scientific congress ACC.23/WC

Cereno Scientific (XSAT: CRNO B) today announced that an abstract on preclinical drug candidate CS585 has been accepted as a moderated poster presentation at the ACC.23/WCC hosted by the American College of Cardiology Together With WCC (World Congress of Cardiology), in New Orleans, US, on March 4-6, 2023. The abstract titled “CS585 is a novel orally available prostacyclin receptor agonist with long-term in vivo inhibition of platelets and thrombosis formation in mouse without increased risk of bleeding” will be presented by Dr. Michael Holinstat, lead of Cereno’s development programs at University of Michigan and Director of Translational Research at Cereno.

The abstract titled “CS585 is a novel orally available prostacyclin receptor agonist with long-term in vivo inhibition of platelets and thrombosis formation in mouse without increased risk of bleeding”, was authored by Michael Holinstat, Sylviane Lambert, Pooja Yalavarthi, Livia Stanger and Adriana Yamaguchi at University of Michigan, Ann Arbor, MI, US; Björn Dahlöf at Cereno Scientific and University of Gothenburg. The abstract has been selected to be presented as a moderated poster presentation by Dr. Michael Holinstat.

The ACC.23/WCC congress is arranged by the American College of Cardiology Together With WCC, March 4-6, 2023, live in New Orleans, LA, US. Research presented at the Annual Scientific Session is a critical contribution to the evolving science and innovative strategies central to the experience. Accepted abstracts will be available through the online eAbstracts system to registered attendees and be published online in the Journal of the American College of Cardiology (JACC), one of the top-ranked cardiovascular journals in the world.

Details on the oral presentation at ACC.23/WCC:

Presentation Title: CS585 IS A NOVEL ORALLY AVAILABLE PROSTACYCLIN RECEPTOR AGONIST WITH LONG-TERM IN VIVO INHIBITION OF PLATELETS AND THROMBOSIS FORMATION IN MOUSE WITHOUT INCREASED RISK OF BLEEDING

Authors: Michael Holinstat, Sylviane Lambert, Pooja Yalavarthi, Livia Stanger, Adriana Yamaguchi, University of Michigan, Ann Arbor, MI, USA; Björn Dahlöf, University of Gothenburg, Gothenburg, Sweden.

Presentation Number: 1082-03

Session Title: Novel Vascular Pharmacotherapeutics

Presentation Date: Monday, Mar 6, 2023

Presentation Time: 9:45am - 9:55am CST

Session Location: Pulmonary Vascular Disease, Valvular Heart Disease, Special Topics Moderated Poster Theater 4_Hall F

For further information, please contact:

Josefine Göranson, Head of IR & Communications
Phone: +46 704 92 35 63
Email: info@cerenoscientific.com

http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist. It has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.